文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

整合酶抑制剂治疗HIV感染者肠道菌群与体重增加的五年纵向研究

Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

这项为期5年的前瞻性纵向研究纳入202例病毒学抑制的HIV感染者,比较以整合酶链转移抑制剂(INSTI)或非核苷类逆转录酶抑制剂(NNRTI)为基础方案者的肠道菌群与显著体重增加的关系。结果显示显著体重增加与特定菌群特征相关,INSTI组中与体重增加相关的Tyzzerella_4和Lactobacillus相对丰度更高。

要点

  • 显著体重增加与Dialister和Tyzzerella_4相关,无显著增重者Phascolarctobacterium富集。
  • INSTI组Tyzzerella_4和Lactobacillus相对丰度高于NNRTI组。
  • 整体体重增加在INSTI与NNRTI组间无差异,提示菌群可能介导代谢结局。

核心结论

  • HIV感染者的显著体重增加与特定肠道菌群特征相关。
  • INSTI方案者中与体重增加相关菌属的富集提示菌群可能介导代谢结局。

研究设计与样本

  • 5年前瞻性纵向研究,纳入202例病毒学抑制且接受INSTI或NNRTI为基础抗逆转录病毒治疗的HIV感染者。
  • 169例完成240周随访,其中63例维持INSTI方案、79例维持NNRTI方案、27例维持NNRTI+INSTI方案。
  • 每年测量体重,显著体重增加定义为连续测量间或与基线比较增加≥10%。
  • 采用Illumina MiSeq平台对16S rRNA基因V3-V4区进行菌群分析。

主要发现

  • 5年体重增加中位数(IQR)为1.3(-2.8至4.5)kg。
  • 70例(34.7%)发生显著体重增加,其中20例(9.9%)为连续测量间增加≥10%,50例(24.8%)为较基线增加≥10%。
  • 按体重增加分组,调整后α多样性和β多样性指数无显著差异。
  • 校正偏倚的组成微生物组分析(bias correction 2模型)显示体重增加与Dialister和Tyzzerella_4属相关,而无显著体重增加者中Phascolarctobacterium富集。
  • INSTI组与NNRTI组整体体重增加无差异,但INSTI组Tyzzerella_4相对丰度更高(0.05% vs 0.02%,P=0.017),Lactobacillus亦更高(0.29% vs 0.22%,P=0.009)。

临床怎么用

  • 对接受INSTI方案的HIV感染者,可关注肠道菌群特征与体重变化的关系。
  • 随访中应定期监测体重,识别显著体重增加者。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the relationship between the gut microbiota composition and significant weight gain in virologically-suppressed people with HIV (PWH) on antiretroviral therapy. METHODS: This 5-year prospective longitudinal study included virologically-suppressed PWH receiving regimens based on the integrase strand transfer inhibitors (INSTIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs). Body weight was measured annually, with significant weight gain defined as a ≥10% increase between consecutive measurements or compared to baseline. Gut microbiota profiling was conducted using 16S rRNA sequencing (V3-V4 regions) via the Illumina MiSeq platform. RESULTS: 202 participants were recruited, with 169 completing the 240-week follow-up. Among these, 63 remained on INSTI-based, 79 on NNRTI-based and 27 on NNRTI + INSTI-based regimens. Median (interquartile range (IQR)) 5-year weight gain was 1.3 (-2.8 to 4.5) kg. Significant weight gain occurred in 70 (34.7%) participants, including 20 (9.9%) with ≥10% gain between consecutive measurements and 50 (24.8%) from baseline. No significant differences were observed in adjusted α- and β-diversity indices between groups defined by weight gain. Adjusted analysis of compositions of microbiomes with bias correction 2 model showed that weight gain was associated with the genera Dialister and Tyzzerella_4, whereas Phascolarctobacterium was enriched in those without significant weight gain. While overall weight gain did not differ between INSTI-based and NNRTI-based groups, participants on INSTIs-based regimens showed higher relative abundances of bacteria linked to weight gain, like Tyzzerella_4 (0.05% versus 0.02%, P = 0.017) and Lactobacillus (0.29% versus 0.22%, P = 0.009). CONCLUSIONS: Significant weight gain in the PWH is associated with distinct gut microbiota profiles. The enrichment of weight gain-associated taxa, such as Tyzzerella_4 and Lactobacillus, in individuals on INSTI-based regimens suggests a potential microbiota-mediated mechanism modulating metabolic outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. García-Abellán J, García JA, Galdámez R, et al. Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study. J Antimicrob Chemother. 2025. PMID: 40470774. doi:10.1093/jac/dkaf182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。